False
March 1, 2023
Discover a comprehensive solution that covers all target regions of major WES panels available in the market. With a target size of 37.1 Mb, the panel does not compromise performance in terms of coverage and uniformity, enabling efficient, cost-effective sequencing of the human whole exome.
For research use only. Not for use in diagnostic procedures.
April 6, 2023
In this study, an established biospecimen provider process a biopsy from a renal cell carcinoma (RCC) tumor using their established SOPs to dissociate fresh tumor tissue, perform flow cytometry, and cryopreserve the sample or capture single cells with the HIVE™ scRNAseq Solution for single cell RNA sequencing. The HIVE™ scRNAseq protocol was easily adopted into their standardized operations.
April 6, 2023
A revolutionary development in the oncology field is the emergence of technologies that enable clinicians to rapidly screen for multiple cancer types using a single blood sample.
These tests, known as multi-cancer early detection (MCED) tests, are designed to detect circulating tumor biomarkers in the blood. And improve early detection, treatment, and outcomes for cancer patients.
Our latest whitepaper summarizes discussions between a panel of industry and academic leaders about the challenges and opportunities of MCED tests.
May 15, 2023
With the Agilent SureSelect Cancer CGP assay, a targeted, pan-cancer panel based on next-generation sequencing (NGS) technology, you’ll have access to the most clinically relevant and up-to-date biomarker content by detecting key classes of somatic alterations. Have confidence in high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimum sample input. The workflow solution is configurable to meet the needs of your lab with options to incorporate sample QC, automation, and data analysis solutions.
September 7, 2023
Fetal Rhesus Factor D (RhD) genotyping is typically performed through non-invasive prenatal testing (NIPT) and is important in identifying RhD incompatibility between mother and child.
The FetoGnost® Kit RHD from Ingenetix allows rapid, sensitive, and non-invasive fetal RhD genotyping of samples purified from maternal plasma of RhD-negative pregnant women, based on real-time PCR technology. In this app note, you will explore the compatibility of the FetoGnost® Kit RHD with extracted cffDNA obtained with the chemagic™ 360 instrument using RhD-positive or -negative plasma from blood donors.
October 5, 2023
With Agilent SureSelect Cancer Tumor-Specific assays, focused cancer NGS panels comprised of approximately 50 genes each, you can detect key classes of somatic alterations (SNVs, CNVs, indels, DNA translocations) from lung, colon, pancreas, kidney, and bladder tissue samples. For de novo gene fusion detection, the modular workflow allows the option to combine a SureSelect Cancer Tumor-Specific DNA assay with SureSelect Cancer CGP RNA assay (80 genes) in the same sequencing run. Obtain high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimal sample input. Workflows are configurable with options to incorporate sample QC, automation, and data analysis solutions.
October 12, 2023
The combination of immunoprecipitation (IP) with MALDI-TOF MS resulted in IP-MALDI-MS, an analytical technique that led to the first successful detection of plasma amyloid-β (Aβ) by mass spectrometry. This helped to identify plasma APP669–711/Aβ1–42 ratio, a novel biomarker that correlates with amyloid PET. Samples from Japan and Australia revealed a high degree of concordance between amyloid PET and plasma APP669–711/Aβ1–42 ratio, plasma Aβ1–40/Aβ1–42 ratio, and a combination of both. With advances in disease-modifying drugs, blood-based biomarkers increase in value due to their role in screening subjects and drug effects, and as adjuncts in the diagnosis of AD.
Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.
False